A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors (NCT02671435)
A Phase 1/2 Study of Durvalumab and Monalizumab in Adult Subjects With Select Advanced Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This is a multicenter, open-label, dose-escalation, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, pharmacokinetic (PK), pharmacodynamics, and immunogenicity of durvalumab (MEDI4736) in combination with monalizumab (IPH2201) in adult participants with selected advanced solid tumors and the combination of durvalumab and monalizumab (IPH2201) standard of care systemic therapy with or without biological agent and monalizumab (IPH2201) with biological agent administered to participants with recurrent or metastatic colorectal cancer (CRC).
Who can join: Review the eligibility criteria below.
Location: Research Site — Birmingham, Alabama
Age range: 18 Years to 99 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (49 Sites)
Showing the first 25 of 49 sites.
- Research Site — Birmingham, Alabama
- Research Site — Scottsdale, Arizona
- Research Site — Duarte, California
- Research Site — La Jolla, California
- Research Site — Los Angeles, California
- Research Site — Sacramento, California
- Research Site — Santa Monica, California
- Research Site — Aurora, Colorado
- Research Site — Tampa, Florida
- Research Site — Chicago, Illinois
- Research Site — Baltimore, Maryland
- Research Site — Boston, Massachusetts
- Research Site — Detroit, Michigan
- Research Site — New Brunswick, New Jersey
- Research Site — New Hyde Park, New York
- Research Site — New York, New York
- Research Site — The Bronx, New York
- Research Site — Providence, Rhode Island
- Research Site — Nashville, Tennessee
- Research Site — Dallas, Texas
- Research Site — San Antonio, Texas
- Research Site — Salt Lake City, Utah
- Research Site — Blacktown,
- Research Site — Clayton,
- Research Site — Waratah,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Solid Tumors
- A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma — Scottsdale, Arizona
- A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer — Orange, California
- QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations — Denver, Colorado
- A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors — Denver, Colorado
- A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer — Scottsdale, Arizona
- A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations — Los Angeles, California
Explore by condition: All Advanced Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.